JP5941841B2 - 周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用 - Google Patents

周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用 Download PDF

Info

Publication number
JP5941841B2
JP5941841B2 JP2012513195A JP2012513195A JP5941841B2 JP 5941841 B2 JP5941841 B2 JP 5941841B2 JP 2012513195 A JP2012513195 A JP 2012513195A JP 2012513195 A JP2012513195 A JP 2012513195A JP 5941841 B2 JP5941841 B2 JP 5941841B2
Authority
JP
Japan
Prior art keywords
influenza virus
antibody
influenza
virus
subtype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012513195A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012527899A (ja
JP2012527899A5 (enExample
Inventor
ガルシア‐サストレ アドルフォ
ガルシア‐サストレ アドルフォ
パレセ ペテル
パレセ ペテル
ティー．ワング タイア
ティー．ワング タイア
Original Assignee
アイカーン スクール オブ メディシン アット マウント サイナイ
アイカーン スクール オブ メディシン アット マウント サイナイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイカーン スクール オブ メディシン アット マウント サイナイ, アイカーン スクール オブ メディシン アット マウント サイナイ filed Critical アイカーン スクール オブ メディシン アット マウント サイナイ
Publication of JP2012527899A publication Critical patent/JP2012527899A/ja
Publication of JP2012527899A5 publication Critical patent/JP2012527899A5/ja
Application granted granted Critical
Publication of JP5941841B2 publication Critical patent/JP5941841B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
JP2012513195A 2009-05-26 2010-05-26 周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用 Expired - Fee Related JP5941841B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US18126309P 2009-05-26 2009-05-26
US61/181,263 2009-05-26
US22430209P 2009-07-09 2009-07-09
US61/224,302 2009-07-09
US30589810P 2010-02-18 2010-02-18
US61/305,898 2010-02-18
PCT/US2010/036170 WO2010138564A1 (en) 2009-05-26 2010-05-26 Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016014445A Division JP2016127846A (ja) 2009-05-26 2016-01-28 周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用

Publications (3)

Publication Number Publication Date
JP2012527899A JP2012527899A (ja) 2012-11-12
JP2012527899A5 JP2012527899A5 (enExample) 2013-07-11
JP5941841B2 true JP5941841B2 (ja) 2016-06-29

Family

ID=42352512

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012513195A Expired - Fee Related JP5941841B2 (ja) 2009-05-26 2010-05-26 周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用
JP2016014445A Pending JP2016127846A (ja) 2009-05-26 2016-01-28 周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用
JP2017239124A Pending JP2018064580A (ja) 2009-05-26 2017-12-14 周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016014445A Pending JP2016127846A (ja) 2009-05-26 2016-01-28 周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用
JP2017239124A Pending JP2018064580A (ja) 2009-05-26 2017-12-14 周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用

Country Status (6)

Country Link
US (3) US8673314B2 (enExample)
EP (1) EP2435475B1 (enExample)
JP (3) JP5941841B2 (enExample)
AU (1) AU2010254136B2 (enExample)
CA (1) CA2800182A1 (enExample)
WO (1) WO2010138564A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2787099A1 (en) 2009-03-30 2010-10-14 Anice C. Lowen Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof
AU2010254136B2 (en) 2009-05-26 2016-09-29 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
US9849192B2 (en) 2009-11-18 2017-12-26 Rutgers, The State University Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
CA2818237C (en) 2009-11-18 2021-05-18 University Of Medicine And Dentistry Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
US9701723B2 (en) 2010-02-18 2017-07-11 Icahn School Of Medicine At Mount Sinai Vaccines for use in the prophylaxis and treatment of influenza virus disease
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
JP6232373B2 (ja) * 2011-04-21 2017-11-15 ナノセラピューティクス・インコーポレイテッドＮａｎｏｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ワクチンから抗原を単離し定量する方法
AR087364A1 (es) * 2011-07-29 2014-03-19 Pf Medicament Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres
CN104114184B (zh) * 2011-08-10 2017-04-19 兰肯瑙医学研究所 用于治疗自身免疫性和炎症性疾病的方法和组合物
GB201115214D0 (en) 2011-09-02 2011-10-19 Health Prot Agency Influenza virus antibody compositions
KR20140068205A (ko) 2011-09-20 2014-06-05 마운트 시나이 스쿨 오브 메디슨 인플루엔자 바이러스 백신 및 이의 용도
JP6325451B2 (ja) 2011-12-02 2018-05-16 アイム・セラピューティクス・べー・フェー Ａ型インフルエンザに特異的な抗体
KR102050615B1 (ko) * 2012-03-08 2019-11-29 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 b 바이러스들에 결합하고 중화할 수 있는 인간 결합 분자 및 그 용도
CN102621320B (zh) * 2012-03-20 2014-07-02 中国检验检疫科学研究院 一种用于快速检测人禽流感病毒的非诊断性双抗体夹心法
EP2904015A4 (en) * 2012-10-02 2016-10-05 Univ Rutgers TARGETED RELEASE OF ANTIBODIES TO ACTIVATED MATRIPTASE-CONJUGATED TOXINS
KR20150104117A (ko) 2012-12-18 2015-09-14 이칸 스쿨 오브 메디슨 엣 마운트 시나이 인플루엔자 바이러스 백신 및 그의 용도
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
CN105209071A (zh) 2013-03-14 2015-12-30 抗非特公司 用于提高疗效的基于鼻内递送中和抗体的组合物和方法
WO2014143886A2 (en) * 2013-03-15 2014-09-18 Edimer Pharmaceuticals, Inc. Anti-ectodysplasin antibodies
JPWO2015025900A1 (ja) * 2013-08-23 2017-03-02 学校法人藤田学園 抗インフルエンザウイルス中和抗体
JP6535675B2 (ja) * 2013-10-02 2019-06-26 メディミューン，エルエルシー 抗ａ型インフルエンザ抗体の中和及びその使用
KR102344390B1 (ko) 2014-02-04 2021-12-28 콘트라펙트 코포레이션 수동 인플루엔자 면역화에 유용한 항체, 및 이의 사용을 위한 조성물, 조합 및 방법
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
EP3274369A4 (en) * 2015-03-27 2018-10-17 University of Southern California Car t-cells for the treatment of b7-h4 expressing solid tumors
WO2016160618A2 (en) 2015-03-27 2016-10-06 University Of Southern California Car t-cell therapy directed to lhr for the treatment of solid tumors
EP3429586A4 (en) 2016-03-18 2020-03-11 Rutgers, the State University of New Jersey TARGETING TUMOR CELLS WITH CHEMOTHERAPEUTIC AGENTS CONJUGATED TO ANTI-MATRIPTASE ANTIBODIES BY IN VIVO-CLAVABLE LINKAGES
EP3455251A4 (en) * 2016-05-09 2020-04-22 Icahn School of Medicine at Mount Sinai WIDE-NEUTRALIZING ANTIBODIES AGAINST HUMAN CYTOMEGALOVIRUS (HCMV) AND METHOD FOR USE THEREOF
WO2017218624A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
US10766968B2 (en) 2017-08-23 2020-09-08 Brown University Methods and compositions relating to anti-CHI3L1 antibody reagents to treat cancer
EP3672636A4 (en) * 2017-08-23 2021-05-12 Brown University PROCEDURES AND COMPOSITIONS RELATED TO ANTI-CHI3L1 ANTIBODY REAGENTS
EP3810634A4 (en) 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
EP3959216A4 (en) 2019-04-24 2023-01-11 Icahn School of Medicine at Mount Sinai ANTI-INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF
IL317519A (en) * 2022-06-09 2025-02-01 Santa Ana Bio Inc Antibodies targeting C-KIT and/or SIGLEC and uses thereof

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA836080B (en) 1982-08-23 1984-04-25 Scripps Clinic Res Broad spectrum influenza antisera
US5182192A (en) * 1987-03-27 1993-01-26 The Wistar Institute Monoclonal antibodies against glycolipid antigens, methods of producing these antibodies, and use therefor
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US6001634A (en) 1989-08-28 1999-12-14 Palese; Peter Recombinant negative strand RNA viruses
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US6887699B1 (en) 1990-05-22 2005-05-03 Medimmune Vaccines, Inc. Recombinant negative strand RNA virus expression systems and vaccines
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
FR2664905B1 (fr) 1990-07-18 1994-08-12 Agronomique Inst Nat Rech Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
JP3037554B2 (ja) * 1993-04-20 2000-04-24 寳酒造株式会社 免疫原性人工ポリペプチド
US5589174A (en) 1992-09-17 1996-12-31 Takara Shuzo Co., Ltd. Anti-human influenza virus antibody
US6337070B1 (en) 1993-04-29 2002-01-08 Takara Shuzo Co., Ltd. Polypeptides for use in generating anti-human influenza virus antibodies
GB9221654D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
WO1994016109A1 (en) 1993-01-15 1994-07-21 Whitehead Institute For Biomedical Research Membrane fusion events and means for altering same
WO1994017826A1 (en) 1993-02-01 1994-08-18 Smithkline Beecham Corporation Vaccinal polypeptides
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
AR025750A1 (es) 1999-09-24 2002-12-11 Smithkline Beecham Biolog Vacunas
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US6632620B1 (en) * 2000-06-22 2003-10-14 Andrew N. Makarovskiy Compositions for identification and isolation of stem cells
US20040091503A1 (en) 2002-08-20 2004-05-13 Genitrix, Llc Lectin compositions and methods for modulating an immune response to an antigen
WO2004067553A2 (en) * 2003-01-29 2004-08-12 The Research Foundation Of The State University Of New York Tolerance-induced targeted antibody production
JP4675317B2 (ja) 2003-01-30 2011-04-20 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アジュバント化インフルエンザワクチン
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
EP1766059B1 (en) 2004-05-25 2012-07-11 MedImmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
CA2598884A1 (en) * 2005-02-24 2006-10-05 University Of Massachusetts Influenza nucleic acids, polypeptides, and uses thereof
EP1885186B1 (en) 2005-06-01 2015-09-02 California Institute Of Technology Method of targeted gene delivery using viral vectors
JP4758148B2 (ja) * 2005-06-14 2011-08-24 泰三 宇田 インフルエンザウイルスのヘマグルチニンに対する抗体酵素
PL1951299T3 (pl) 2005-11-04 2012-07-31 Novartis Ag Szczepionki przeciw grypie zawierające kombinacje adiuwantów cząsteczkowych i czynników wzmacniających immunogenność
EP2251034B1 (en) 2005-12-02 2018-02-14 Icahn School of Medicine at Mount Sinai Chimeric newcastle disease viruses presenting non-native surface proteins and uses thereof
ES2385842T3 (es) 2005-12-06 2012-08-01 Yeda Research And Development Co., Ltd. Vacuna mejorada contra la gripe
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
WO2007134327A2 (en) 2006-05-15 2007-11-22 Sea Lane Biotechnologies, Llc. Neutralizing antibodies to influenza viruses
US8148085B2 (en) * 2006-05-15 2012-04-03 Sea Lane Biotechnologies, Llc Donor specific antibody libraries
WO2008054540A2 (en) 2006-05-18 2008-05-08 Pharmexa Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
AU2007275010B2 (en) 2006-07-21 2013-06-20 California Institute Of Technology Targeted gene delivery for dendritic cell vaccination
CA2663388C (en) 2006-09-07 2017-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
WO2008032219A2 (en) 2006-09-11 2008-03-20 Novartis Ag Making influenza virus vaccines without using eggs
CN101607995B (zh) 2007-06-15 2013-05-01 厦门大学 特异性结合h5亚型禽流感病毒血凝素蛋白的单克隆抗体或其结合活性片段及其用途
EP2014279A1 (en) 2007-06-22 2009-01-14 Pevion Biotech AG Virosomes comprising hemagglutinin derived from an influenza virus produced in a cell line, compositions, methods of manufacturing, use thereof
JP5187883B2 (ja) * 2007-07-18 2013-04-24 独立行政法人科学技術振興機構 抗原ペプチドおよびその利用
US20090092635A1 (en) * 2007-08-17 2009-04-09 Wyeth Heterologous prime-boost immunization regimen
FR2921387B1 (fr) 2007-09-26 2012-04-20 Sanofi Pasteur Procede de production du virus de la grippe
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
MX2010006148A (es) 2007-12-06 2011-02-23 Dana Farber Cancer Inst Inc Anti-cuerpos contra el virus de la influenza y metodos de uso de los mismos.
WO2009121004A2 (en) 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc Neutralizing molecules to viral antigens
GB0905570D0 (en) 2009-03-31 2009-05-13 Novartis Ag Combined vaccines
CA2787099A1 (en) 2009-03-30 2010-10-14 Anice C. Lowen Influenza virus hemagglutinin polypeptides containing stem domains, vaccines and uses thereof
WO2010130636A1 (en) 2009-05-11 2010-11-18 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
AU2010254136B2 (en) 2009-05-26 2016-09-29 Mount Sinai School Of Medicine Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
JP5871796B2 (ja) 2009-06-24 2016-03-01 メディカゴ インコーポレイテッド ヘマグルチニンを含むキメラインフルエンザウイルス様粒子
CA2805505C (en) 2009-07-30 2021-08-03 Mount Sinai School Of Medecine Chimeric influenza viruses having reduced ability to reassort with other influenza viruses and uses thereof
US9701723B2 (en) 2010-02-18 2017-07-11 Icahn School Of Medicine At Mount Sinai Vaccines for use in the prophylaxis and treatment of influenza virus disease
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
EP2596017B1 (en) 2010-07-22 2019-04-03 John W. Schrader Cross-protective antibody against influenza viral infection
KR20140068205A (ko) 2011-09-20 2014-06-05 마운트 시나이 스쿨 오브 메디슨 인플루엔자 바이러스 백신 및 이의 용도
KR20150104117A (ko) 2012-12-18 2015-09-14 이칸 스쿨 오브 메디슨 엣 마운트 시나이 인플루엔자 바이러스 백신 및 그의 용도

Also Published As

Publication number Publication date
JP2016127846A (ja) 2016-07-14
EP2435475A1 (en) 2012-04-04
US20150239960A1 (en) 2015-08-27
CA2800182A1 (en) 2010-12-02
JP2012527899A (ja) 2012-11-12
AU2010254136A1 (en) 2012-01-19
US8673314B2 (en) 2014-03-18
US9175069B2 (en) 2015-11-03
JP2018064580A (ja) 2018-04-26
US20110027270A1 (en) 2011-02-03
AU2010254136B2 (en) 2016-09-29
US20140170163A1 (en) 2014-06-19
WO2010138564A1 (en) 2010-12-02
EP2435475B1 (en) 2018-10-17

Similar Documents

Publication Publication Date Title
JP5941841B2 (ja) 周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用
US12030928B2 (en) Anti-influenza B virus neuraminidase antibodies and uses thereof
US10544207B2 (en) Antibodies against influenza virus hemagglutinin and uses thereof
US12024552B2 (en) Ha binding agents
CN102939096B (zh) 用于预防和治疗流感病毒疾病的疫苗
JP2018134107A (ja) インフルエンザウイルスワクチン及びその使用
KR20130075732A (ko) 인플루엔자 바이러스 백신 및 이의 용도
EP2295465A2 (en) Human monoclonal antibodies to influenza M2 protein and methods of making and using same
JP2019521674A (ja) インフルエンザウイルス血球凝集素タンパク質及びその使用
US12545718B2 (en) Anti-influenza B virus neuraminidase antibodies and uses thereof
BR112014028109B1 (pt) Novos agentes de ligação de ha

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130521

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141014

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150413

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160128

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160331

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160426

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160523

R150 Certificate of patent or registration of utility model

Ref document number: 5941841

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees